Intestinal microflora has been implicated in the etiology of ulcerative colitis.
Over the past few years, the use of probiotics in ulcerative colitis has gained attention.
Dr Yukiko Tsuda and colleagues from Japan evaluated the efficacy of probiotics therapy for mild to moderate distal ulcerative colitis refractory to conventional therapies.
The research team assessed 20 patients with mild to moderate distal ulcerative colitis who took 9 BIO-THREE tablets per day for 4 weeks.
|Remission was observed in 45% of the patients|
|Scandinavian Journal of Gastroenterology|
Clinical symptoms and endoscopic findings were evaluated as ulcerative colitis disease activity index scores before and after administration of BIO-THREE.
Fecal samples were collected from all patients before and after probiotics administration.
The team analyzed fecal microflora by the terminal restriction fragment length polymorphism method.
The researchers observed remission in 45% of the patients, a response in 10%, no response in 40%, and worsening in 5%.
Terminal restriction fragment length polymorphism analysis indicated that the principal alteration in microflora was an increase in bifidobacteria.
Dr Tsuda's team concluded, "This study showed that administration of BIO-THREE improved the clinical symptoms and endoscopic findings in patients with ulcerative colitis"
"We also found that administration of BIO-THREE is safe and efficacious for the treatment of ulcerative colitis."